Folic acid-modified biocompatible Pullulan/poly(acrylic acid) nanogels for targeted delivery to MCF-7 cancer cells.

Autor: Ghaffarlou M; Hacettepe University, Department of Chemistry, Beytepe, 06800 Ankara, Turkey., Sütekin SD; Hacettepe University, Department of Chemistry, Beytepe, 06800 Ankara, Turkey., Karacaoğlu E; Hacettepe University, Department of Biology, Beytepe, 06800 Ankara, Turkey., Karahisar Turan S; Hacettepe University, Department of Biology, Beytepe, 06800 Ankara, Turkey., İnci ÖG; Hacettepe University, Department of Chemistry, Beytepe, 06800 Ankara, Turkey., Güven O; Hacettepe University, Department of Chemistry, Beytepe, 06800 Ankara, Turkey., Barsbay M; Hacettepe University, Department of Chemistry, Beytepe, 06800 Ankara, Turkey. Electronic address: mbarsbay@hacettepe.edu.tr.
Jazyk: angličtina
Zdroj: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2023 Mar; Vol. 184, pp. 189-201. Date of Electronic Publication: 2023 Feb 09.
DOI: 10.1016/j.ejpb.2023.02.001
Abstrakt: We prepared a novel nanogel consisting of poly(acrylic acid) (PAA) and pullulan (Pull) via a facile and green irradiation protocol. Synthesized nanogels were modified with bovine serum albumin (BSA) and folic acid (FA) and then loaded with doxorubicin (DOX) to obtain a delivery system with tumor-specific targeting ability and enhanced biocompatibility. In-vitro DOX release was investigated at different pH values, and it was found that DOX release was higher in acidic media, which is an advantage for the internalization of nanoparticles in acidic tumor environment. MTT assay and DAPI staining were performed to evaluate the effects of nanogels on L929 and MCF-7 cells. Based on the results of in vitro studies, DOX-loaded nanogels were found to be effective on cancer cells, while the neat ones were nondestructive in both lines. Overall, we envision that the biocompatible and tumor-specific nanogels could be a promising safe drug carrier system for cancer therapy.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: